Satraplatin activation by haemoglobin, cytochrome C and liver microsomes in vitro.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2006, v. 57, n. 4, p. 483, doi. 10.1007/s00280-005-0069-5
- By:
- Publication type:
- Article
Works by Tingle, Malcolm D.
Results: 16
1
2
Rapid biotransformation of satraplatin by human red blood cells in vitro.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2002, v. 50, n. 1, p. 9, doi. 10.1007/s00280-002-0462-2
- By:
- Publication type:
- Article
3
Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
- Published in:
- Cancer Chemotherapy & Pharmacology, 2002, v. 49, n. 2, p. 126, doi. 10.1007/s00280-001-0383-5
- By:
- Publication type:
- Article
4
A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2001, v. 47, n. 6, p. 541, doi. 10.1007/s002800100285
- By:
- Publication type:
- Article
5
In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2001, v. 47, n. 4, p. 319, doi. 10.1007/s002800000249
- By:
- Publication type:
- Article
6
Reversible binding of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid to plasma proteins and its distribution into blood cells in various species.
- Published in:
- Journal of Pharmacy & Pharmacology, 2001, v. 53, n. 4, p. 463, doi. 10.1211/0022357011775758
- By:
- Publication type:
- Article
7
COMPARATIVE PROTEIN BINDING, STABILITY AND DEGRADATION OF SATRAPLATIN, JM118 AND CISPLATIN IN HUMAN PLASMA IN VITRO.
- Published in:
- Clinical & Experimental Pharmacology & Physiology, 2008, v. 35, n. 12, p. 1440, doi. 10.1111/j.1440-1681.2008.05017.x
- By:
- Publication type:
- Article
8
Contrasting effects of acute and chronic dietary exposure to 2-amino-3-methyl-imidazo[4,5-f]quinoline (IQ) on xenobiotic metabolising enzymes in the male Fischer 344 Rat: implications for chemoprevention studies.
- Published in:
- European Journal of Nutrition, 2001, v. 40, n. 1, p. 39, doi. 10.1007/PL00007384
- By:
- Publication type:
- Article
9
Circulating microRNA as biomarkers of clozapine-induced cardiotoxicity.
- Published in:
- Biomarkers, 2020, v. 25, n. 1, p. 76, doi. 10.1080/1354750X.2019.1693631
- By:
- Publication type:
- Article
10
A pharmacokinetic framework describing antibiotic adsorption to cardiopulmonary bypass devices.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2024, v. 13, n. 8, p. 1409, doi. 10.1002/psp4.13180
- By:
- Publication type:
- Article
11
The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation N. A. Helsby et al. Cyclophosphamide activation by CYP2C19 and CYP2B6.
- Published in:
- British Journal of Clinical Pharmacology, 2010, v. 70, n. 6, p. 844, doi. 10.1111/j.1365-2125.2010.03789.x
- By:
- Publication type:
- Article
12
Validation of an LC–MS Method for the Detection and Quantification of BZP and TFMPP and their Hydroxylated Metabolites in Human Plasma and its Application to the Pharmacokinetic Study of TFMPP in Humans.
- Published in:
- Journal of Forensic Sciences, 2010, v. 55, n. 5, p. 1311, doi. 10.1111/j.1556-4029.2010.01457.x
- By:
- Publication type:
- Article
13
Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes.
- Published in:
- British Journal of Clinical Pharmacology, 2001, v. 52, n. 2, p. 129, doi. 10.1046/j.0306-5251.2001.01438.x
- By:
- Publication type:
- Article
14
Ethnic disparity in clozapine dosing and cardiotoxicity in New Zealand.
- Published in:
- 2022
- By:
- Publication type:
- journal article
15
Metabolizing enzyme localization and activities in the first trimester human placenta: the effect of maternal and gestational age, smoking and alcohol consumption.
- Published in:
- 2002
- By:
- Publication type:
- journal article
16
Varenicline improves motor and cognitive symptoms in early Huntington's disease.
- Published in:
- Neuropsychiatric Disease & Treatment, 2016, v. 12, p. 2381, doi. 10.2147/NDT.S111083
- By:
- Publication type:
- Article